

Media Release of October 31, 2017

BB Biotech statement on MiFID II

Under the European Union's new Markets in Financial Instruments Directive MiFID II that enters into effect at the beginning of 2018, financial services providers will be required to provide clients with a transparent disclosure of research costs and state how those costs will be absorbed. Bellevue Asset Management, the company retained by BB Biotech, will absorb the costs incurred for research and will not pass them onto its shareholders.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.